The safety profile of DUPIXENT + TCS in children
through Week 16 was similar to that in adults1

Adverse reactions occurring in ≥1% of adult patients through Week 161
Injection site reaction
DUPIXENTc
(n=529) %
10%
Placebo
(n=517) %
5%
Conjunctivitisd
DUPIXENTc
(n=529) %
10%
Placebo
(n=517) %
2%
Blepharitis
DUPIXENTc
(n=529) %
<1%
Placebo
(n=517) %
<1%
Oral herpes
DUPIXENTc
(n=529) %
4%
Placebo
(n=517) %
2%
Keratitise
DUPIXENTc
(n=529) %
<1%
Placebo
(n=517) %
0%
Eye pruritus
DUPIXENTc
(n=529) %
1%
Placebo
(n=517) %
<1%
Oral herpes simplex virus infectionf
DUPIXENTc
(n=529) %
2%
Placebo
(n=517) %
1%
Dry eye
DUPIXENTc
(n=529) %
<1%
Placebo
(n=517) %
0%
Injection site reaction
DUPIXENT + TCSc
(n=110) %
10%
Placebo + TCS
(n=315) %
6%
Conjunctivitisd
DUPIXENT + TCSc
(n=110) %
9%
Placebo + TCS
(n=315) %
5%
Blepharitis
DUPIXENT + TCSc
(n=110) %
5%
Placebo + TCS
(n=315) %
1%
Oral herpes
DUPIXENT + TCSc
(n=110) %
3%
Placebo + TCS
(n=315) %
2%
Keratitise
DUPIXENT + TCSc
(n=110) %
4%
Placebo + TCS
(n=315) %
0%
Eye pruritus
DUPIXENT + TCSc
(n=110) %
2%
Placebo + TCS
(n=315) %
1%
Oral herpes simplex virus infectionf
DUPIXENT+ TCSc
(n=110) %
1%
Placebo + TCS
(n=315) %
<1%
Dry eye
DUPIXENT+ TCSc
(n=110) %
2%
Placebo + TCS
(n=315) %
<1%

Treatment-emergent eosinophilia (≥5,000 cells/mcL) was reported in1:

  • <3% of DUPIXENT-treated subjects and <0.5% of placebo-treated subjects (SOLO 1, SOLO 2, and AD-1021; DRI12544, QUEST, and VOYAGE; SINUS-24 and SINUS-52; PRIME and PRIME2)g
  • 8% of DUPIXENT-treated subjects and 0% of placebo-treated subjects (AD-1539)

a Pooled analysis of SOLO 1, SOLO 2, and AD-1021 (phase 2 dose-ranging study).1

b Analysis of CHRONOS in which subjects were on background TCS therapy.1

cDUPIXENT 600 mg at Week 0, followed by 300 mg every 2 weeks.1

d Conjunctivitis cluster includes conjunctivitis, allergic conjunctivitis, bacterial conjunctivitis, viral conjunctivitis, giant papillary conjunctivitis, eye irritation, and eye inflammation.1

e Keratitis cluster includes keratitis, ulcerative keratitis, allergic keratitis, atopic keratoconjunctivitis, and ophthalmic herpes simplex.1

f Other herpes simplex virus infection cluster includes herpes simplex, genital herpes, herpes simplex otitis externa, and herpes virus infection, but excludes eczema herpeticum.1

gDRI12544, QUEST, and VOYAGE are part of the asthma clinical trial program; SINUS-24 and SINUS-52 are part of the chronic rhinosinusitis with nasal polyposis clinical trial program; PRIME and PRIME2 are part of the prurigo nodularis clinical trial program.1

Numerically fewer children treated with DUPIXENT + TCS developed skin infections compared with placebo + TCS in AD-16522,h
  • 7% of children <30 kg treated with DUPIXENT 300 mg Q4W + TCS and 9% of children ≥30 kg treated with DUPIXENT 200 mg Q2W + TCS vs 13% with placebo + TCS

h Data reflect adjudicated nonherpetic skin infections through Week 16.

Long-term safety profile observed in children

The long-term safety of DUPIXENT ± TCS in children was assessed in an open-label extension study (AD-1434)1

  • The safety profile through Week 52 was similar to the safety profile observed through Week 16 in AD-1652
  • The long-term safety profile of DUPIXENT ± TCS in children was consistent with that seen in adults and adolescents

DUPIXENT demonstrated a generally consistent safety profile through Week 16 across multiple age populations as young as 6 months of age1

Discontinuation rates due to adverse events in children treated with DUPIXENT + TCS were comparable to those with placebo + TCS3,i
  • 0.8% of children treated with DUPIXENT + TCS (n=242) discontinued treatment through Week 16 vs 1.7% of children treated with placebo + TCS (n=120) discontinued treatment through Week 16 (AD-1652)

iAnalysis done in overall study population.

Patients should discontinue DUPIXENT if a clinically significant hypersensitivity reaction occurs or until a parasitic (helminth) infection resolves in a patient who does not respond to anti-helminth treatment.1

Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with DUPIXENT1
  • Avoid use of live vaccines during treatment with DUPIXENT1
Other attributes &
important considerations

NOT AN IMMUNOSUPPRESSANT1

NO INITIAL LAB TESTING OR ONGOING
LAB MONITORING, according to the
Prescribing Information1

NO KNOWN DRUG-TO-DRUG
INTERACTIONS1

  • Not metabolized through the liver or excreted
    through the kidneys

NO BOXED WARNING1

Please see additional Warnings and
Precautions in the Prescribing Information
and Important Safety Information below.

Select important
safety information

WARNINGS AND PRECAUTIONS

  • Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT